Zai Lab (09688) surged over 5%, and as of press time, the stock was up 5.38% to HK$25.48, with a turnover of HK$224 million.

On the news front, Zai Lab recently announced that according to Amgen, the company's partner and sponsor of the study, the FORTITUDE-101 Phase III clinical trial evaluating bemarituzumab in combination with chemotherapy (mFOLFOX6) for first-line gastric cancer treatment has completed its final analysis. At the pre-specified interim analysis (primary analysis) of this study, the bemarituzumab plus chemotherapy regimen demonstrated statistically significant and clinically meaningful improvement in overall survival compared to chemotherapy alone. However, in the final analysis, the previously observed survival benefit was attenuated.

Amgen stated that results from both the interim and final analyses will be presented at upcoming major medical conferences. Based on the updated results from the FORTITUDE-101 study, the company plans to await results from the FORTITUDE-102 study (which aims to evaluate bemarituzumab in combination with nivolumab and chemotherapy in the same patient population) before submitting registration applications. Data from the FORTITUDE-102 study is expected to be released in late 2025 or the first half of 2026.